Devyser Diagnostics AB Net Assets
Devyser Diagnostics AB net assets. Based on the latest financial reports, Devyser Diagnostics AB (DVYSR) has net assets worth Skr381.00 Million SEK (≈ $41.00 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr493.10 Million ≈ $53.07 Million USD) and total liabilities (Skr112.10 Million ≈ $12.06 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Devyser Diagnostics AB (DVYSR) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr381.00 Million |
| % of Total Assets | 77.27% |
| Annual Growth Rate | 42.31% |
| 5-Year Change | -14.97% |
| 10-Year Change | N/A |
| Growth Volatility | 439.49 |
Net Assets of Devyser Diagnostics AB (2018–2025)
Net assets of Devyser Diagnostics AB from 2018 to 2025. This chart illustrates how Devyser Diagnostics AB's net assets have evolved over time, based on quarterly financial data. See Devyser Diagnostics AB (DVYSR) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Devyser Diagnostics AB (2018–2025)
The table below shows the annual net assets of Devyser Diagnostics AB from 2018 to 2025. For live market cap and overall valuation, see how much is Devyser Diagnostics AB worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr354.30 Million ≈ $38.13 Million |
+1.52% |
| 2024-12-31 | Skr349.00 Million ≈ $37.56 Million |
-9.37% |
| 2023-12-31 | Skr385.10 Million ≈ $41.44 Million |
-10.74% |
| 2022-12-31 | Skr431.44 Million ≈ $46.43 Million |
+3.54% |
| 2021-12-31 | Skr416.68 Million ≈ $44.84 Million |
+1254.05% |
| 2020-12-31 | Skr30.77 Million ≈ $3.31 Million |
-16.85% |
| 2019-12-31 | Skr37.01 Million ≈ $3.98 Million |
+23.50% |
| 2018-12-31 | Skr29.97 Million ≈ $3.23 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Devyser Diagnostics AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18645700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Devyser Diagnostics AB Net Assets Breakdown (December 2025)
Devyser Diagnostics AB net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr1.00 Million | 0.28% |
| Other Comprehensive Income | Skr2.60 Million | 0.73% |
| Other Components | Skr545.60 Million | 153.99% |
| Total Equity | Skr354.30 Million | 100.00% |
Devyser Diagnostics AB Competitors by Market Cap
The table below lists competitors of Devyser Diagnostics AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Adel Kalemcilik Ticaret ve Sanayi AS
IS:ADEL
|
$116.88 Million |
|
Kulmbacher Brauerei Aktien-Gesellschaft
MU:KUL
|
$116.93 Million |
|
Gold Resource Corporation
NYSE MKT:GORO
|
$116.96 Million |
|
Data International Co Ltd
TWO:5432
|
$116.99 Million |
|
Yapi Kredi Koray Gayrimenkul Yatirim Ortakligi AS
IS:KGYO
|
$116.83 Million |
|
Willbes
KO:008600
|
$116.83 Million |
|
Anavex Life Sciences Corp
NASDAQ:AVXL
|
$116.80 Million |
|
Creative Newtech Limited
NSE:CREATIVE
|
$116.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Devyser Diagnostics AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 349,100,000 to 354,300,000, a change of 5,200,000 (1.5%).
- Net loss of 8,400,000 reduced equity.
- New share issuances of 9,400,000 increased equity.
- Other comprehensive income increased equity by 2,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-8.40 Million | -2.37% |
| Share Issuances | Skr9.40 Million | +2.65% |
| Other Comprehensive Income | Skr2.00 Million | +0.56% |
| Other Changes | Skr2.20 Million | +0.62% |
| Total Change | Skr- | 1.49% |
Book Value vs Market Value Analysis
This analysis compares Devyser Diagnostics AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.01x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 6.44x to 3.01x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | Skr9.98 | Skr64.30 | x |
| 2019-12-31 | Skr12.20 | Skr64.30 | x |
| 2020-12-31 | Skr10.60 | Skr64.30 | x |
| 2021-12-31 | Skr37.10 | Skr64.30 | x |
| 2022-12-31 | Skr27.10 | Skr64.30 | x |
| 2023-12-31 | Skr23.80 | Skr64.30 | x |
| 2024-12-31 | Skr21.29 | Skr64.30 | x |
| 2025-12-31 | Skr21.35 | Skr64.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Devyser Diagnostics AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3.35%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.33x
- Recent ROE (-2.37%) is above the historical average (-8.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 1.73% | 1.08% | 1.00x | 1.61x | Skr-2.48 Million |
| 2019 | 18.94% | 10.90% | 0.87x | 1.99x | Skr3.31 Million |
| 2020 | -35.46% | -16.61% | 0.88x | 2.42x | Skr-13.99 Million |
| 2021 | -4.97% | -22.17% | 0.20x | 1.10x | Skr-62.40 Million |
| 2022 | -10.65% | -36.29% | 0.25x | 1.16x | Skr-89.10 Million |
| 2023 | -13.92% | -31.66% | 0.33x | 1.32x | Skr-92.11 Million |
| 2024 | -17.62% | -28.35% | 0.46x | 1.36x | Skr-96.41 Million |
| 2025 | -2.37% | -3.35% | 0.53x | 1.33x | Skr-43.83 Million |
Industry Comparison
This section compares Devyser Diagnostics AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $416,764,988
- Average return on equity (ROE) among peers: -38.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Devyser Diagnostics AB (DVYSR) | Skr381.00 Million | 1.73% | 0.29x | $116.87 Million |
| Acarix A/S (ACARIX) | $38.17 Million | -125.99% | 0.27x | $24.00 Million |
| Arcoma AB (ARCOMA) | $44.04 Million | -16.97% | 0.80x | $12.32 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $373.35 Million | -10.28% | 0.81x | $51.45 Million |
| BICO Group AB (BICO) | $3.10 Billion | -37.83% | 0.95x | $179.52 Million |
| Boule Diagnostics AB (BOUL) | $462.50 Million | 2.75% | 0.64x | $4.97 Million |
| CellaVision AB (CEVI) | $66.67 Million | 0.00% | 0.27x | $512.85 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $19.46 Million | -85.28% | 0.14x | $9.20 Million |
| Chordate Medical Holding AB (CMH) | $29.55 Million | -46.39% | 0.39x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $29.82 Million | -34.38% | 0.50x | $82.28 Million |
| Duearity AB (DEAR) | $3.79 Million | -34.93% | 0.15x | $331.97K |
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, … Read more